A team of scientists at Dynamis significantly decreased kidney and retina Rage in aged rats that were orally dosed with company’s Rage inhibitor for 32 weeks, as compared to non-treated rats. In addition, several other new compounds also inhibited Rage in a variety of cells grown in culture.
Scientists believe that a Rage inhibitor would be an important addition to the arsenal of drugs to treat diabetic kidney disease, retinopathy, microvascular disease, Alzheimer’s, inflammatory diseases, some cancers, and aging. A patent has been filed on the discovery.
Annette Tobia, president and founder of Dynamis, said: “We are very excited about these results, since discovering Rage inhibitors enables company to develop a treatment for diabetic kidney disease and blindness.”